Atria Investments Inc decreased its position in British American Tobacco p.l.c. (NYSE:BTI – Free Report) by 53.7% in the 4th ...

BioXcel Therapeutics (BTAI) announced that, following the successful raise of $14 million gross proceeds in an equity financing that closed on ...

BioXcel Therapeutics (NASDAQ:BTAI – Get Free Report) is expected to be posting its quarterly earnings results before the market opens on Tuesday, March 11th. Analysts expect BioXcel Therapeutics to ...

Small-Cap Firms Were Last Week’s Top Performers. In this article, we are going to take a look at where BioXcel Therapeutics, ...

BioXcel said the Phase 3 trial is designed to evaluate the safety of BXCL501. The trial's topline-data results, which are expected in the second half of 2025, are intended to support a potential ...

BioXcel Therapeutics (BTAI) announced it has reached 33% enrollment in its 200-patient SERENITY At-Home trial. The Phase 3 trial is designed to ...

Mobile World Congress (MWC) 2025 by unveiling cutting-edge Distributed Antenna System (DAS) and Private Mobile Network solutions designed to enhance connectivity in the 5G+ era.

BTI Wireless made waves at Mobile World Congress (MWC) 2025 by unveiling cutting-edge Distributed Antenna System (DAS) and ...

ScPharmaceuticals, Inc. (SCPH) is expected to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended December 2024. This widely-known consensus ...

BioXcel Therapeutics, Inc. (the “Company”) (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to ...

BioXcel Therapeutics (BTAI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

BioXcel Therapeutics, Inc. (NASDAQ: BTAI) shares are trading higher Monday following news that the U.S. Food and Drug ...